Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094649 | 0.91 | TRPA1 (0.54) | TRPA1ADORA2ARXRARXRBRXRG | |
| SCHEMBL20088560 | 0.90 | ADORA2A (0.42) | TRPA1ADORA2ARXRARXRBRXRG | |
| SCHEMBL20088571 | 0.89 | TRPA1 (0.47) | TRPA1ADORA2ARXRARXRBRXRG | |
| SCHEMBL20088603 | 0.88 | TRPA1 (0.46) | TRPA1ADORA2ARXRARXRBRXRG | |
| SCHEMBL20094265 | 0.88 | TRPA1 (0.46) | TRPA1ADORA2ARXRARXRBRXRG | |
| SCHEMBL20088610 | 0.87 | TRPA1 (0.47) | TRPA1ACACBACACA | |
| SCHEMBL20088606 | 0.87 | TRPA1 (0.47) | TRPA1RXRARXRBRXRGTRPM8 | |
| SCHEMBL20088575 | 0.84 | TRPA1 (0.43) | TRPA1ADORA2AMAPTMGLL | |
| SCHEMBL20088609 | 0.84 | TRPA1 (0.47) | TRPA1ADORA2AMAPTMGLL | |
| SCHEMBL20088658 | 0.83 | TRPA1 (0.48) | TRPA1ADORA2ARXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN3A, GRM1 | TRPA1 593/4885ADORA2A 186/4885RXRA 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.